Candel $200m cash balance, advances aglatimagene toward planned BLA filing in Q4 2026
Candel Therapeutics posts Q2 2026 EPS -0.52 on $0 revenue, discloses $201.6M cash balance
- Q2 2026 non-GAAP EPS was -0.52 (-478% YoY) on revenue of $0, missing EPS but beating revenue estimates.
- Q2 2026 net loss totaled $38.9 million, as disclosed in Candel Therapeutics’ latest SEC filing.
- Cash balance of $201.6 million supports a projected cash runway extending into the first quarter of 2028.
- Company advances aglatimagene program toward a planned Biologics License Application filing in the fourth quarter of 2026.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.